A single immediate postoperative prophylactic intravesical instillation of Pirarubicin following transurethral resection of non-muscle invasive bladder cancer

A single immediate postoperative prophylactic intravesical instillation of Pirarubicin following transurethral resection of non-muscle invasive bladder cancer - A single immediate postoperative prophylactic intravesical instillation of Pirarubicin for non-muscle invasive bladder cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004378

Enrollment

Registered

2010-10-21

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-muscle invasive bladder cancer (pTa and low grade)

Interventions

Immediate intravesical instillation of Pirarubicin 30 mg following transurethral resection of bladder cancer

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) non-muscle invasive bladder cancer (pTa and low grade). (2) Curative resection of all visible tumor can be performed. (3) non-muscle invasive bladder cancer without any CIS element (4) Function of all organs are within normal range (5) ECOG performance status, 0-2

Exclusion criteria

Exclusion criteria: (1) patients with duplex of active other malignant disease. (2) Patients with history or present disease of upper urinary tract utotherial carcinoma. (3) Patients with severe disfunction of renal, liver, hematopoietic or heart. (4) Patients with history of allergic reaction against doxorubicin or epirubicin

Design outcomes

Primary

Measure	Time frame
Duration of recurrence-free survival	—

Secondary

Measure	Time frame
Two-year recurrence free survival rate Safty	—

Countries

Japan

Contacts

Public ContactHideaki Miyake

Kobe University Graduate School of Medicine Division of Urology

hideakimiyake@hotmail.com078-382-6155

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026